MOUNTAIN VIEW, Calif. / Oct 05, 2023 / Business Wire / Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. (“Pearsanta”). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business (“B2B”) and direct-to-consumer (“DTC”) clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers.

“Naming Ernie as CEO of Pearsanta, is a crucial initial step in our plan to scale the company and capitalize on global opportunities. With Ernie at the helm, we believe that Test2Treat.me has the potential to quickly fill a void in the healthcare market for DTC point-of-care testing and treatment,” says Amro Albanna, co-founder, chairman, and CEO of Aditxt.

Mr. Lee brings over two decades of experience in the development and distribution of innovative products and services to healthcare providers. Previously, Mr. Lee was the CEO and Chief Marketing Officer of FirstVitals Health and Wellness Inc., where he received the 2012 Health Care Innovation Award from the Centers for Medicare & Medicaid Services for the implementation of early diabetes remote patient monitoring and care management services for Medicaid’s underserved beneficiaries using a proprietary remote patient monitoring platform. Mr. Lee holds a patent for an innovative electronic healthcare payment system connecting insurance payers and healthcare providers.

“I am excited to lead a company focused on the power of health by the numbers. Episodic care will never be the same again with the advent of our Test2Treat.me platform,” says Lee. “With physician shortages and limited access to immediate care, Test2Treat.me meets patient demand for personalized medicine that makes a real difference in how efficiently patients are tested and treated. Additionally, with increasing out-of-pocket costs for healthcare services, we believe consumers will seek best-in-class clinical diagnostic laboratory and professional services as direct purchasers of healthcare services. Lessons learned from the COVID experience: consumers are expecting rapid turnaround time for lab tests with the convenience of online consultations with healthcare providers, and Test2Treat.me was designed to meet this new demand.”

Visit Test2Treat.me and Pearsanta.com to stay up to date on upcoming product developments. Visit Aditxt.com to learn more about the life-changing health technology innovations the company discovers, develops, and deploys that invoke global change around immune health care.

About Aditxt, Inc.

Aditxt, Inc.® (NASDAQ: ADTX) is a global innovation company focused on discovering, developing and deploying technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by our growing ecosystem of research institutions, global industry partners, and shareholders who inform and inspire our mission. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, VA. For more information, visit the Company’s websites at www.Aditxt.com, www.Adimune.com, and www.Pearsanta.com. Follow us on LinkedIn for the latest company news.

About Pearsanta, Inc.

Formed in January 2023 as a wholly owned Aditxt subsidiary, Pearsanta, Inc., is responding to a growing demand for convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere. The company specializes in bio sample collection, processing, and reporting to deliver actionable information to the end user by utilizing collection devices, point-of-care (POC) technologies, Lab Developed Test (LDT) assays, a data-driven analysis engine and telemedicine. The initial Test2Treat.me platform will be available at-home, in pharmacies and physician’s offices and offer diagnostic testing for SARs-CoV-2, respiratory syncytial virus (RSV) and influenza A/B, urinary tract infections (UTIs) and sexually transmitted infections (STIs).

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company’s ability to finance and execute on its strategic M&A initiatives; the Company’s ability obtain the necessary funding and partner to commence clinical trials; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.